Spots Global Cancer Trial Database for lymphoblastic leukemia, acute, childhood
Every month we try and update this database with for lymphoblastic leukemia, acute, childhood cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | NCT05495035 | Lymphoblastic L... Leukemia, Lymph... Relapsed Leukem... Refractory Leuk... | Olverembatinib,... | 1 Year - 18 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL | NCT05440409 | Leukemia, Acute... Lymphoblastic L... | 3 Years - 25 Years | National Institutes of Health Clinical Center (CC) | ||
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT01186328 | Lymphoblastic L... Lymphoblastic L... Leukemia, Lymph... Leukemia, Lymph... | EZN-3042 Cytarabine Doxorubicin Prednisone Vincristine PEG-asparaginas... Methotrexate Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia | NCT05043571 | Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... CAR CAR T-Cell-Rela... Refractory Leuk... | CAR T-cell ther... | 6 Months - 65 Years | National University Hospital, Singapore | |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | NCT01321346 | Lymphoblastic L... Myelogenous Leu... Hodgkin's Disea... Non-Hodgkin's L... | Panobinostat Cytarabine Panobinostat | 8 Years - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | NCT03817320 | ALL, Childhood Lymphoblastic L... Lymphoblastic L... | Ixazomib Vincristine Dexamethasone Asparaginase Doxorubicin Methotrexate (I... Triple IT (Meth... Leucovorin | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors | NCT01100658 | ALL, Childhood Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... Lymphocytic Leu... Lymphocytic Leu... Lymphocytic Leu... Brain Tumors Cancer of the B... Cancer of Brain Malignant Prima... Brain Neoplasms... | Methylphenidate Placebo | 8 Years - 17 Years | University of Minnesota | |
| Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol | NCT03022747 | Lymphoblastic L... | Allopurinol Standard treatm... | 6 Months - 19 Years | Vastra Gotaland Region | |
| A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL) | NCT00991133 | Lymphoblastic L... | Clofarabine inc... | 1 Year - 30 Years | Sanofi | |
| Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | NCT02906371 | Lymphoblastic L... | Tocilizumab Tocilizumab CART 19 | 1 Year - 24 Years | University of Pennsylvania | |
| A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma | NCT01614197 | Lymphoblastic L... Lymphoblastic L... Peripheral T-ce... | Temsirolimus Etoposide Cyclophosphamid... Methotrexate Hydrocortisone Cytarabine | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | NCT05495035 | Lymphoblastic L... Leukemia, Lymph... Relapsed Leukem... Refractory Leuk... | Olverembatinib,... | 1 Year - 18 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors | NCT01100658 | ALL, Childhood Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Leukemia, Lymph... Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... Lymphocytic Leu... Lymphocytic Leu... Lymphocytic Leu... Brain Tumors Cancer of the B... Cancer of Brain Malignant Prima... Brain Neoplasms... | Methylphenidate Placebo | 8 Years - 17 Years | University of Minnesota | |
| EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT01186328 | Lymphoblastic L... Lymphoblastic L... Leukemia, Lymph... Leukemia, Lymph... | EZN-3042 Cytarabine Doxorubicin Prednisone Vincristine PEG-asparaginas... Methotrexate Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML | NCT01861002 | Lymphoblastic L... Myelogenous Leu... | Azacytidine Fludarabine Cytarabine Intrathecal (IT... Intrathecal Met... | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL) | NCT00991133 | Lymphoblastic L... | Clofarabine inc... | 1 Year - 30 Years | Sanofi | |
| Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL | NCT02879643 | ALL, Childhood Lymphoblastic L... Lymphoblastic L... | Marqibo | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | NCT03817320 | ALL, Childhood Lymphoblastic L... Lymphoblastic L... | Ixazomib Vincristine Dexamethasone Asparaginase Doxorubicin Methotrexate (I... Triple IT (Meth... Leucovorin | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL | NCT02879643 | ALL, Childhood Lymphoblastic L... Lymphoblastic L... | Marqibo | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
